Meeting News

Geographic atrophy progression mostly unchanged with treat-and-extend ranibizumab for wet AMD

Peter J. Kertes

CHICAGO — A 24-month treat-and-extend analysis trial with ranibizumab for patients with neovascular age-related macular degeneration showed the progression of geographic atrophy was mostly unchanged in trial participants, according to a speaker here.

“Based on the current analysis, the progression of geographic atrophy was mostly unchanged over 24 months in most of our subjects and comparable between treat-and-extend and the monthly regimen,” Peter J. Kertes, MD, FRCS(C), said at the American Society of Retina Specialists annual meeting.

The open-label CANTREAT trial included 580 patients with neovascular AMD randomly assigned 1:1 to a monthly or treat-and-extend injection therapy of ranibizumab. Researchers evaluated changes in best corrected visual acuity and geographic atrophy from baseline to month 12, from month 12 to month 24, and from baseline to month 24, Kertes said.

Kertes and researchers evaluated 164 patients with fundus autofluorescence taken at baseline to evaluate the change in geographic atrophy.

From baseline to month 12, 61.4% of treat-and-extend patients experienced no change in geographic atrophy compared with 58.8% of patients in the monthly cohort. From baseline to month 24, 51.2% of patients in the treat-and-extend cohort experienced no geographic atrophy change compared with 58% of monthly patients, Kertes said.

“From baseline to month 24, the majority of patients did not show a significant increase in their geographic atrophy, but there was some progression in somewhat more patients. Most importantly, there were no differences between the group randomized to treat-and-extend and the group randomized to monthly treatment,” he said.

Treat-and-extend patients underwent a statistically significant fewer number of injections over the 24-month study compared with the monthly treatment group. At 12 months, the treat-and-extend group underwent a mean of 9.4 injections compared with a mean of 11.8 injections in the monthly group. At 24 months, the treat-and-extend group underwent a mean of 17.6 injections compared with a mean of 23.5 injections in the monthly group. – by Robert Linnehan

Reference:

Kertes PJ. Geographic atrophy in the Canadian treat and extend trial with Ranibizumab in nAMD patients: CANTREAT study 24-month results. Presented at: American Society of Retina Specialists annual meeting; July 27-30, 2019; Chicago.

Disclosure: Kertes reports he receives research funding from Bayer, Allergan, Alcon, Novartis, Roche and Genentech, sits on advisory boards for Novartis, Alcon and Bayer, receives travel grants from Novartis and Bayer, and owns stock in ArcticDx.

Peter J. Kertes

CHICAGO — A 24-month treat-and-extend analysis trial with ranibizumab for patients with neovascular age-related macular degeneration showed the progression of geographic atrophy was mostly unchanged in trial participants, according to a speaker here.

“Based on the current analysis, the progression of geographic atrophy was mostly unchanged over 24 months in most of our subjects and comparable between treat-and-extend and the monthly regimen,” Peter J. Kertes, MD, FRCS(C), said at the American Society of Retina Specialists annual meeting.

The open-label CANTREAT trial included 580 patients with neovascular AMD randomly assigned 1:1 to a monthly or treat-and-extend injection therapy of ranibizumab. Researchers evaluated changes in best corrected visual acuity and geographic atrophy from baseline to month 12, from month 12 to month 24, and from baseline to month 24, Kertes said.

Kertes and researchers evaluated 164 patients with fundus autofluorescence taken at baseline to evaluate the change in geographic atrophy.

From baseline to month 12, 61.4% of treat-and-extend patients experienced no change in geographic atrophy compared with 58.8% of patients in the monthly cohort. From baseline to month 24, 51.2% of patients in the treat-and-extend cohort experienced no geographic atrophy change compared with 58% of monthly patients, Kertes said.

“From baseline to month 24, the majority of patients did not show a significant increase in their geographic atrophy, but there was some progression in somewhat more patients. Most importantly, there were no differences between the group randomized to treat-and-extend and the group randomized to monthly treatment,” he said.

Treat-and-extend patients underwent a statistically significant fewer number of injections over the 24-month study compared with the monthly treatment group. At 12 months, the treat-and-extend group underwent a mean of 9.4 injections compared with a mean of 11.8 injections in the monthly group. At 24 months, the treat-and-extend group underwent a mean of 17.6 injections compared with a mean of 23.5 injections in the monthly group. – by Robert Linnehan

Reference:

Kertes PJ. Geographic atrophy in the Canadian treat and extend trial with Ranibizumab in nAMD patients: CANTREAT study 24-month results. Presented at: American Society of Retina Specialists annual meeting; July 27-30, 2019; Chicago.

Disclosure: Kertes reports he receives research funding from Bayer, Allergan, Alcon, Novartis, Roche and Genentech, sits on advisory boards for Novartis, Alcon and Bayer, receives travel grants from Novartis and Bayer, and owns stock in ArcticDx.

    See more from American Society of Retina Specialists Meeting